Previous 10 | Next 10 |
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C., Nov....
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2019 on Tuesday, Nove...
Over the past month, lots of biotech stocks have been hammered for reasons that aren't always clear. The market has made mistakes in the past and investors are right to assume it may have gone too far with some of these unfortunate companies. Can any of these beaten-down drugmakers bounce back?...
Shares of G1 Therapeutics (NASDAQ: GTHX) fell 37.2% in September, according to data from S&P Global Market Intelligence , after investors reacted to trial data for some of the biopharmaceutical company's cancer drug candidates. To be sure, shares plunged 33% on Monday, Se...
The European Society for Medical Oncology (ESMO) meeting, which wrapped up on Tuesday, featured presentations from a few smaller companies that saw their stock prices move substantially after the meeting. Data source: YCharts. Seattle Genetics wowed investors with a pair of clinical trials. ...
Major benchmarks gained ground on Monday, finishing the third quarter on an optimistic note. Investors have gotten whipsawed on various news items coming out of Washington, and today's more positive tone in trade relations with China improved market sentiment. Yet there were still some big chall...
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this Read more ...
Gainers: Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...
-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced ...
-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients receiving trilaciclib and chemotherapy in combination with Tecentriq ® -- ...
News, Short Squeeze, Breakout and More Instantly...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 AD...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...